FDA breakthrough status given to PhaseBio's PB2452

06:23 EDT 9 Apr 2019 | SmartBrief

PhaseBio Pharmaceuticals' PB2452, being developed as a reversal agent for AstraZeneca's anti-clotting drug Brilinta, or ticag -More

Original Article: FDA breakthrough status given to PhaseBio's PB2452


More From BioPortfolio on "FDA breakthrough status given to PhaseBio's PB2452"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...